

Technology Advisory Committee C Interests Register

Topic [ID6164]

Publication Date: 06 March 2024 (expected)

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|---|------------------------|--------------------|--|-------------------|---|
| Dr Kate Ren | TAC C Committee Member | Financial Interest | Dr Kate Ren has provided statistical methodology consultancy service for Pfizer (Tofacitinib for patients with moderate-to-severe ulcerative colitis). | 10/10/2023 | It was agreed that Dr Kate Ren's declaration would not prevent her from participating in discussions on this appraisal. |
| Michael Chambers | TAC C Committee Member | Financial Interest | Michael Chambers has participated in an advisory panel for Pfizer (manufacturer of possible comparator) in an unrelated disease area (prostate cancer). | 10/10/2023 | It was agreed that Michael Chambers's declaration would not prevent him from participating in discussions on this appraisal. |
| Dr Satish Venkateshan - New committee member (observing) | TAC C Committee Member | Financial Interest | Dr Satish Venkateshan works for Regeneron, pharmaceuticals/biotech company. Satish also owns shares in the company and has stock options. Regeneron has products including in development that are being assessed in a variety of solid tumours. | 10/10/2023 | It was agreed that Dr Satish Venkateshan's declaration would not prevent him from participating in discussions on this appraisal. |

| Name | Role with NICE | Type of interest | Description of interest | Interest declared | Comments |
|------------------|-----------------|--|---|------------------------------|--|
| Chiara Braconi | Clinical expert | Direct – Financial Direct non – Financial | Chiara Braconi has received honoraria as a speaker and advisor from Servier. Chiara has received research funds from Servier. Chiara Braconi has received speaker fees from Incyte and AstraZeneca, advisory fee from AstraZeneca, Chiara also has a spouse employee in AstraZeneca. | 30/08/2023 30/08/2023 | It was agreed that Chiara Braconi's declaration would not prevent her from providing expert advice to the committee. |
| John Bridgewater | Clinical expert | Direct – Financial Non – Financial Professional | John Bridgewater received speaker fees and research funding from Incyte. John has provided consultancy for Roche, Bayer, AstraZeneca, Incyte, Taiho and Servier. John was an investigator in ProviDHe trial and other trials involving ivosidenib. John was an investigator in ABC-06 trial involving mFOLFOX | 02/10/2023 10/10/2023 | It was agreed that John Bridgewater's declaration would not prevent him from providing expert advice to the committee. |
| Helen Morement | Patient expert | Organisational interests (AMMF) | Helen Morement has received sponsorship from Servier in the last 12 months. | 20/02/2023 | It was agreed that Helen Morement's declaration would not prevent her |

| Name | Role with NICE | Type of interest | Description of interest | | | Interest declared | Comments | | | | | | | | | |
|------------|---|------------------|---|--|--|-------------------|----------|--------|------------|---|------------|------------|--------------------------|------------|--|--|
| | | | <ul style="list-style-type: none">Sponsorship received: <table><tr><th>Date</th><th>Project</th><th>Amount</th></tr><tr><td>22/10/2022</td><td>AMMF Patient Organisation CCA Information Project</td><td>£21,272.97</td></tr><tr><td>16/05/2023</td><td>AMMF CCA Conference 2023</td><td>£15,000.00</td></tr></table> | | | Date | Project | Amount | 22/10/2022 | AMMF Patient Organisation CCA Information Project | £21,272.97 | 16/05/2023 | AMMF CCA Conference 2023 | £15,000.00 | | from providing expert advice to the committee. |
| Date | Project | Amount | | | | | | | | | | | | | | |
| 22/10/2022 | AMMF Patient Organisation CCA Information Project | £21,272.97 | | | | | | | | | | | | | | |
| 16/05/2023 | AMMF CCA Conference 2023 | £15,000.00 | | | | | | | | | | | | | | |